Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMA NASDAQ:ADVM NASDAQ:APTO NASDAQ:ELEV NASDAQ:MIRO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$18.43-0.2%$19.78$10.21▼$25.67$4.40B0.433.68 million shs989,227 shsADVMAdverum Biotechnologies$2.55-6.2%$2.48$1.78▼$10.14$52.85M0.7264,077 shs44,883 shsAPTOAptose Biosciences$4.41$1.35▼$50.10$3.66M1.04227,964 shs650,294 shsELEVElevation Oncology$0.38-1.0%$0.35$0.22▼$3.28$22.27M1.481.49 million shs374,027 shsMIROMiromatrix Medical$3.39$3.38$0.91▼$4.35$92.95M0.0180,095 shsN/A2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics+0.71%+0.96%-11.46%-4.79%+53.92%ADVMAdverum Biotechnologies+7.09%+14.05%-2.51%-20.70%-65.04%APTOAptose Biosciences0.00%0.00%0.00%0.00%-92.21%ELEVElevation Oncology-0.92%-1.66%-1.07%+35.21%-85.66%MIROMiromatrix Medical0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMAADMA Biologics4.1804 of 5 stars3.72.00.00.03.02.53.1ADVMAdverum Biotechnologies4.0962 of 5 stars3.43.00.04.80.02.50.6APTOAptose Biosciences1.2629 of 5 stars3.80.00.00.00.60.00.0ELEVElevation Oncology1.7415 of 5 stars3.02.00.00.01.21.70.6MIROMiromatrix MedicalN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMAADMA Biologics 3.33Buy$27.6750.73% UpsideADVMAdverum Biotechnologies 2.80Moderate Buy$23.80847.83% UpsideAPTOAptose Biosciences 3.50Strong Buy$6.00∞ UpsideELEVElevation Oncology 2.00Hold$3.39800.46% UpsideMIROMiromatrix Medical 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ELEV, MIRO, ADVM, APTO, and ADMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/26/2025ADVMAdverum BiotechnologiesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$16.00 ➝ $12.006/10/2025ELEVElevation OncologyJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform6/10/2025ELEVElevation OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Neutral6/9/2025ELEVElevation OncologyTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/9/2025ELEVElevation OncologyWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/15/2025ADVMAdverum BiotechnologiesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$5.00 ➝ $4.005/15/2025ADVMAdverum BiotechnologiesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$33.00 ➝ $33.005/15/2025ADVMAdverum BiotechnologiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.005/8/2025ADMAADMA BiologicsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetStrong-Buy ➝ Strong-Buy$25.00 ➝ $32.004/17/2025ADVMAdverum BiotechnologiesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $33.004/16/2025ADVMAdverum BiotechnologiesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$10.00 ➝ $5.00(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMAADMA Biologics$426.45M10.28$0.54 per share33.88$1.48 per share12.40ADVMAdverum Biotechnologies$1M52.46N/AN/A$3.40 per share0.74APTOAptose BiosciencesN/AN/AN/AN/A($0.19) per shareN/AELEVElevation OncologyN/AN/AN/AN/A$1.02 per shareN/AMIROMiromatrix Medical$958.03K97.02N/AN/A$1.25 per share2.71Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMAADMA Biologics$197.67M$0.8521.5026.60N/A45.01%47.16%30.51%8/6/2025 (Estimated)ADVMAdverum Biotechnologies-$130.93M-$6.40N/AN/AN/AN/A-130.53%-66.31%8/11/2025 (Estimated)APTOAptose Biosciences-$51.21M-$89.19N/AN/AN/AN/A-5,683.22%-300.44%N/AELEVElevation Oncology-$44.49M-$0.82N/AN/AN/AN/A-74.68%-48.14%8/5/2025 (Estimated)MIROMiromatrix Medical-$29.96M-$1.14N/A∞N/A-2,861.17%-120.49%-90.70%N/ALatest ELEV, MIRO, ADVM, APTO, and ADMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025ELEVElevation Oncology-$0.26N/AN/AN/AN/AN/A5/15/2025Q1 2025ELEVElevation Oncology-$0.20-$0.24-$0.04-$0.24N/AN/A5/7/2025Q1 2025ADMAADMA Biologics$0.16$0.14-$0.02$0.11$116.40 million$114.80 million4/15/2025Q4 2024ADVMAdverum Biotechnologies-$1.34-$1.96-$0.62-$1.96N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMAADMA BiologicsN/AN/AN/AN/AN/AADVMAdverum BiotechnologiesN/AN/AN/AN/AN/AAPTOAptose BiosciencesN/AN/AN/AN/AN/AELEVElevation OncologyN/AN/AN/AN/AN/AMIROMiromatrix MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMAADMA Biologics0.226.583.36ADVMAdverum BiotechnologiesN/A3.573.57APTOAptose BiosciencesN/A1.051.05ELEVElevation Oncology0.6719.4019.40MIROMiromatrix Medical0.023.463.46Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMAADMA Biologics75.68%ADVMAdverum Biotechnologies48.17%APTOAptose Biosciences26.62%ELEVElevation Oncology83.70%MIROMiromatrix Medical29.38%Insider OwnershipCompanyInsider OwnershipADMAADMA Biologics3.50%ADVMAdverum Biotechnologies6.00%APTOAptose Biosciences1.33%ELEVElevation Oncology8.10%MIROMiromatrix Medical5.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMAADMA Biologics530238.73 million230.38 millionOptionableADVMAdverum Biotechnologies19020.89 million19.64 millionOptionableAPTOAptose Biosciences312.14 million63.45 millionNo DataELEVElevation Oncology4059.22 million54.43 millionOptionableMIROMiromatrix Medical7627.42 million25.99 millionOptionableELEV, MIRO, ADVM, APTO, and ADMA HeadlinesRecent News About These CompaniesUnited Therapeutics and Intermountain Health Announce the First Patient Treated With External Liver Support Using a Bioengineered Liver - MorningstarJune 25, 2025 | morningstar.comMIntermountain Health patient first to be treated with external bioengineered liverJune 25, 2025 | ksl.comKTurning pig organs to human organsOctober 22, 2024 | mndaily.comMUniversity of Minnesota Venture Center Director Russ Straate retiresOctober 16, 2024 | bizjournals.comBioLargo, Inc.: Clyra Medical Technologies, a Subsidiary of BioLargo, Appoints Dr. Steven J. Kavros as Chief Medical OfficerSeptember 9, 2024 | finanznachrichten.deClyra Medical Technologies Appoints Dr. Steven J. Kavros as Chief Medical OfficerSeptember 9, 2024 | finance.yahoo.comUnited Therapeutics to build $100M pig-to-human organ research center in southeast MinnesotaAugust 15, 2024 | startribune.comSWalter Reed Army Medical CenterMarch 2, 2024 | military.comMQ4 2023 United Therapeutics Corp Earnings CallFebruary 22, 2024 | uk.finance.yahoo.comSouthwest Virginia scientists are gene-editing pigs for human transplantsDecember 19, 2023 | cardinalnews.orgCBest Stocks to Buy Right NowNovember 22, 2023 | benzinga.comMiromatrix Holder Says It Omitted United Therapeutics Deal InfoNovember 16, 2023 | news.bloomberglaw.comNMiromatrix Medical GAAP EPS of -$0.24, revenue of $11.17MNovember 15, 2023 | msn.comMiromatrix Reports Third Quarter 2023 ResultsNovember 14, 2023 | finance.yahoo.comMiromatrix Medical climbs 225% following $140m United Therapeutics bidOctober 31, 2023 | proactiveinvestors.comUnited Therapeutics agrees to buy Miromatrix MedicalOctober 31, 2023 | msn.comUnited Therapeutics looks to hog bioengineered organ R&D with $91M Miromatrix buyOctober 31, 2023 | fiercebiotech.comFMiromatrix Medical Shares Triple After United Therapeutics OfferOctober 31, 2023 | marketwatch.comUnited Therapeutics buying Miromatrix for up to $140MOctober 30, 2023 | bioworld.comBEden Prairie biotech company Miromatrix Medical sells for $91MOctober 30, 2023 | startribune.comSNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeWhy Centene Stock Dropped 40% — And Whether It's a Buy NowBy Leo Miller | July 8, 2025View Why Centene Stock Dropped 40% — And Whether It's a Buy Now3 Overbought Stocks Ripe for a PullbackBy Ryan Hasson | July 7, 2025View 3 Overbought Stocks Ripe for a PullbackELEV, MIRO, ADVM, APTO, and ADMA Company DescriptionsADMA Biologics NASDAQ:ADMA$18.43 -0.04 (-0.20%) As of 03:11 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Adverum Biotechnologies NASDAQ:ADVM$2.55 -0.17 (-6.21%) As of 03:11 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.Aptose Biosciences NASDAQ:APTOAptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.Elevation Oncology NASDAQ:ELEV$0.38 0.00 (-0.95%) As of 03:11 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.Miromatrix Medical NASDAQ:MIROMiromatrix Medical Inc., a life sciences company, develops a novel technology for bioengineering fully transplantable organs. The company's proprietary technology is a platform that uses a two-step method of decellularization and recellularization designed to remove the porcine cells from the organs obtained from pigs and replace them with unmodified human cells. It has collaborations with Baxter, CareDx, The Mayo Clinic, Mount Sinai Hospital, and The Texas Heart Institute. The company was formerly known as TayTech, Inc. Miromatrix Medical Inc. was incorporated in 2009 and is headquartered in Eden Prairie, Minnesota. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
